These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 31836120)
1. Reversible anisocoria due to inadvertent ocular exposure to topical anticholinergic treatment for primary axillary hyperhidrosis. Pashaei-Marandi A; Assam JH; Arnold A; Lee AG; Bonelli L Can J Ophthalmol; 2019 Dec; 54(6):e300-e302. PubMed ID: 31836120 [No Abstract] [Full Text] [Related]
2. Pharmacologic anisocoria secondary to topical glycopyrronium for axillary hyperhidrosis: an emerging clinical presentation. Kaufman AR; Gulati S; Curnyn KM Can J Ophthalmol; 2020 Oct; 55(5):464. PubMed ID: 32735775 [No Abstract] [Full Text] [Related]
3. Use of gloves when applying topical glycopyrronium for treatment of primary axillary hyperhidrosis. Siscos SM; Figenshau K; Rajpara A J Am Acad Dermatol; 2020 Oct; 83(4):e275. PubMed ID: 31846717 [No Abstract] [Full Text] [Related]
4. Mydriasis and anisocoria in a pediatric hyperhidrosis patient with interesting findings in the family cat. Sandhu M; Eisenstein K Pediatr Dermatol; 2023 Jan; 40(1):210-211. PubMed ID: 36263444 [TBL] [Abstract][Full Text] [Related]
5. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis. Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial. Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049 [TBL] [Abstract][Full Text] [Related]
7. Mydriasis secondary to use of glycopyrrolate cream. Radotra A; Baneke A; Paul B Br J Hosp Med (Lond); 2019 Dec; 80(12):736. PubMed ID: 31822169 [No Abstract] [Full Text] [Related]
8. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis. Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409 [TBL] [Abstract][Full Text] [Related]
9. Dilated Pupil in a Patient With Hyperhidrosis. Micieli R; Micieli JA JAMA; 2019 Jul; 322(3):264-265. PubMed ID: 31219503 [No Abstract] [Full Text] [Related]
17. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study. Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881 [TBL] [Abstract][Full Text] [Related]
18. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318 [TBL] [Abstract][Full Text] [Related]
19. Anisocoria secondary to antiperspirant wipes in a pediatric population: a case series. Pecha JD; Yen KG; Moisiuc A; Cantor A J AAPOS; 2022 Feb; 26(1):42-43. PubMed ID: 34798293 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of oral anticholinergics for sympathetic overactivity in a thoracic surgery clinic. Hynes CF; Seevaratnam S; Gesuwan K; Margolis M; Marshall MB J Thorac Cardiovasc Surg; 2016 Aug; 152(2):565-8. PubMed ID: 27160942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]